Annual EBITDA
-$37.87 M
-$5.92 M-18.53%
December 31, 2023
Summary
- As of February 8, 2025, SLS annual EBITDA is -$37.87 million, with the most recent change of -$5.92 million (-18.53%) on December 31, 2023.
- During the last 3 years, SLS annual EBITDA has fallen by -$20.89 million (-122.99%).
- SLS annual EBITDA is now -1474.59% below its all-time high of -$2.40 million, reached on December 31, 2006.
Performance
SLS EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$7.33 M
+$292.00 K+3.83%
September 30, 2024
Summary
- As of February 8, 2025, SLS quarterly EBITDA is -$7.33 million, with the most recent change of +$292.00 thousand (+3.83%) on September 30, 2024.
- Over the past year, SLS quarterly EBITDA has increased by +$848.00 thousand (+10.37%).
- SLS quarterly EBITDA is now -183.82% below its all-time high of $8.74 million, reached on December 31, 2016.
Performance
SLS Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$32.77 M
+$2.03 M+5.84%
September 30, 2024
Summary
- As of February 8, 2025, SLS TTM EBITDA is -$32.77 million, with the most recent change of +$2.03 million (+5.84%) on September 30, 2024.
- Over the past year, SLS TTM EBITDA has increased by +$5.10 million (+13.46%).
- SLS TTM EBITDA is now -4178.33% below its all-time high of -$766.00 thousand, reached on December 31, 2006.
Performance
SLS TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
SLS EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -18.5% | +10.4% | +13.5% |
| 3 y3 years | -123.0% | +19.0% | -21.7% |
| 5 y5 years | -75.8% | +19.0% | -21.7% |
SLS EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -93.3% | at low | -1422.9% | +56.2% | -67.3% | +14.7% |
| 5 y | 5-year | -123.0% | at low | -1422.9% | +56.2% | -116.1% | +14.7% |
| alltime | all time | -1474.6% | +13.6% | -183.8% | +56.2% | -4178.3% | +30.9% |
SELLAS Life Sciences EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$7.33 M(-3.8%) | -$32.77 M(-5.8%) |
| Jun 2024 | - | -$7.62 M(-21.0%) | -$34.80 M(-3.9%) |
| Mar 2024 | - | -$9.64 M(+18.0%) | -$36.23 M(-4.3%) |
| Dec 2023 | -$37.87 M(+18.5%) | -$8.18 M(-12.6%) | -$37.87 M(+30.0%) |
| Sep 2023 | - | -$9.36 M(+3.4%) | -$29.14 M(+8.2%) |
| Jun 2023 | - | -$9.05 M(-19.8%) | -$26.92 M(+1.6%) |
| Mar 2023 | - | -$11.28 M(-2136.3%) | -$26.50 M(-17.1%) |
| Dec 2022 | -$31.95 M(+63.1%) | $554.00 K(-107.8%) | -$31.95 M(-16.8%) |
| Sep 2022 | - | -$7.15 M(-17.1%) | -$38.42 M(+0.4%) |
| Jun 2022 | - | -$8.62 M(-48.5%) | -$38.25 M(+12.2%) |
| Mar 2022 | - | -$16.73 M(+182.7%) | -$34.08 M(+74.0%) |
| Dec 2021 | -$19.59 M(+15.4%) | -$5.92 M(-15.2%) | -$19.59 M(+9.9%) |
| Sep 2021 | - | -$6.98 M(+56.7%) | -$17.83 M(+16.2%) |
| Jun 2021 | - | -$4.45 M(+98.4%) | -$15.35 M(+1.2%) |
| Mar 2021 | - | -$2.25 M(-46.0%) | -$15.16 M(-10.7%) |
| Dec 2020 | -$16.98 M(-1.3%) | -$4.16 M(-7.4%) | -$16.98 M(-2.8%) |
| Sep 2020 | - | -$4.49 M(+5.3%) | -$17.47 M(+1.8%) |
| Jun 2020 | - | -$4.27 M(+5.0%) | -$17.16 M(+1.5%) |
| Mar 2020 | - | -$4.06 M(-12.5%) | -$16.91 M(-1.7%) |
| Dec 2019 | -$17.21 M(-20.1%) | -$4.65 M(+11.0%) | -$17.21 M(-8.7%) |
| Sep 2019 | - | -$4.18 M(+4.1%) | -$18.86 M(+6.3%) |
| Jun 2019 | - | -$4.02 M(-7.8%) | -$17.73 M(-12.3%) |
| Mar 2019 | - | -$4.36 M(-30.7%) | -$20.21 M(-6.2%) |
| Dec 2018 | -$21.54 M(+3.1%) | -$6.29 M(+105.6%) | -$21.54 M(-1.0%) |
| Sep 2018 | - | -$3.06 M(-52.9%) | -$21.76 M(-6.0%) |
| Jun 2018 | - | -$6.50 M(+14.4%) | -$23.16 M(+3.7%) |
| Mar 2018 | - | -$5.68 M(-12.7%) | -$22.33 M(+5.7%) |
| Dec 2017 | -$20.90 M(+30.7%) | -$6.51 M(+46.0%) | -$21.11 M(+260.5%) |
| Sep 2017 | - | -$4.46 M(-21.3%) | -$5.86 M(-25.3%) |
| Jun 2017 | - | -$5.67 M(+26.8%) | -$7.84 M(-31.3%) |
| Mar 2017 | - | -$4.47 M(-151.1%) | -$11.40 M(-28.3%) |
| Dec 2016 | -$15.98 M(-53.1%) | $8.74 M(-235.7%) | -$15.89 M(-50.7%) |
| Sep 2016 | - | -$6.44 M(-30.2%) | -$32.23 M(-6.0%) |
| Jun 2016 | - | -$9.23 M(+3.0%) | -$34.30 M(+0.7%) |
| Mar 2016 | - | -$8.96 M(+18.1%) | -$34.06 M(+0.4%) |
| Dec 2015 | -$34.11 M | -$7.59 M(-10.8%) | -$33.91 M(-5.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2015 | - | -$8.51 M(-5.4%) | -$36.02 M(-5.4%) |
| Jun 2015 | - | -$9.00 M(+2.1%) | -$38.07 M(-14.7%) |
| Mar 2015 | - | -$8.81 M(-9.1%) | -$44.63 M(-5.9%) |
| Dec 2014 | -$43.81 M(+55.4%) | -$9.69 M(-8.3%) | -$47.43 M(+6.3%) |
| Sep 2014 | - | -$10.57 M(-32.1%) | -$44.62 M(+9.3%) |
| Jun 2014 | - | -$15.55 M(+33.9%) | -$40.82 M(+22.9%) |
| Mar 2014 | - | -$11.62 M(+68.8%) | -$33.21 M(+17.8%) |
| Dec 2013 | -$28.20 M(+33.3%) | -$6.88 M(+1.7%) | -$28.20 M(+4.9%) |
| Sep 2013 | - | -$6.77 M(-14.9%) | -$26.90 M(+4.8%) |
| Jun 2013 | - | -$7.95 M(+20.2%) | -$25.66 M(+9.7%) |
| Mar 2013 | - | -$6.61 M(+18.5%) | -$23.39 M(+10.6%) |
| Dec 2012 | -$21.15 M(+71.6%) | -$5.58 M(+0.9%) | -$21.15 M(+10.6%) |
| Sep 2012 | - | -$5.53 M(-2.7%) | -$19.13 M(+12.5%) |
| Jun 2012 | - | -$5.68 M(+30.1%) | -$17.00 M(+25.5%) |
| Mar 2012 | - | -$4.37 M(+22.8%) | -$13.55 M(-6.0%) |
| Dec 2011 | -$12.32 M(-25.1%) | -$3.56 M(+4.8%) | -$14.42 M(-0.7%) |
| Sep 2011 | - | -$3.39 M(+52.1%) | -$14.51 M(-1.9%) |
| Jun 2011 | - | -$2.23 M(-57.4%) | -$14.80 M(-14.4%) |
| Mar 2011 | - | -$5.24 M(+43.5%) | -$17.28 M(+5.0%) |
| Dec 2010 | -$16.45 M(-5.2%) | -$3.65 M(-0.7%) | -$16.45 M(-3.5%) |
| Sep 2010 | - | -$3.68 M(-21.9%) | -$17.05 M(-1.5%) |
| Jun 2010 | - | -$4.71 M(+6.7%) | -$17.32 M(-1.8%) |
| Mar 2010 | - | -$4.41 M(+3.8%) | -$17.64 M(+1.6%) |
| Dec 2009 | -$17.36 M(+20.4%) | -$4.25 M(+7.9%) | -$17.36 M(+1.5%) |
| Sep 2009 | - | -$3.94 M(-21.7%) | -$17.10 M(+3.1%) |
| Jun 2009 | - | -$5.03 M(+21.8%) | -$16.59 M(+4.5%) |
| Mar 2009 | - | -$4.13 M(+3.5%) | -$15.87 M(+10.0%) |
| Dec 2008 | -$14.42 M(+26.5%) | -$3.99 M(+16.3%) | -$14.42 M(+9.4%) |
| Sep 2008 | - | -$3.43 M(-20.4%) | -$13.18 M(+4.3%) |
| Jun 2008 | - | -$4.31 M(+60.7%) | -$12.63 M(-4.3%) |
| Mar 2008 | - | -$2.68 M(-2.4%) | -$13.20 M(+10.7%) |
| Dec 2007 | -$11.40 M(+374.1%) | -$2.75 M(-4.7%) | -$11.93 M(+19.9%) |
| Sep 2007 | - | -$2.88 M(-41.0%) | -$9.94 M(+40.9%) |
| Jun 2007 | - | -$4.89 M(+247.5%) | -$7.06 M(+225.0%) |
| Mar 2007 | - | -$1.41 M(+83.6%) | -$2.17 M(+183.6%) |
| Dec 2006 | -$2.40 M | -$766.00 K | -$766.00 K |
FAQ
- What is SELLAS Life Sciences annual EBITDA?
- What is the all time high annual EBITDA for SELLAS Life Sciences?
- What is SELLAS Life Sciences annual EBITDA year-on-year change?
- What is SELLAS Life Sciences quarterly EBITDA?
- What is the all time high quarterly EBITDA for SELLAS Life Sciences?
- What is SELLAS Life Sciences quarterly EBITDA year-on-year change?
- What is SELLAS Life Sciences TTM EBITDA?
- What is the all time high TTM EBITDA for SELLAS Life Sciences?
- What is SELLAS Life Sciences TTM EBITDA year-on-year change?
What is SELLAS Life Sciences annual EBITDA?
The current annual EBITDA of SLS is -$37.87 M
What is the all time high annual EBITDA for SELLAS Life Sciences?
SELLAS Life Sciences all-time high annual EBITDA is -$2.40 M
What is SELLAS Life Sciences annual EBITDA year-on-year change?
Over the past year, SLS annual EBITDA has changed by -$5.92 M (-18.53%)
What is SELLAS Life Sciences quarterly EBITDA?
The current quarterly EBITDA of SLS is -$7.33 M
What is the all time high quarterly EBITDA for SELLAS Life Sciences?
SELLAS Life Sciences all-time high quarterly EBITDA is $8.74 M
What is SELLAS Life Sciences quarterly EBITDA year-on-year change?
Over the past year, SLS quarterly EBITDA has changed by +$848.00 K (+10.37%)
What is SELLAS Life Sciences TTM EBITDA?
The current TTM EBITDA of SLS is -$32.77 M
What is the all time high TTM EBITDA for SELLAS Life Sciences?
SELLAS Life Sciences all-time high TTM EBITDA is -$766.00 K
What is SELLAS Life Sciences TTM EBITDA year-on-year change?
Over the past year, SLS TTM EBITDA has changed by +$5.10 M (+13.46%)